fond(4)
fond(6)
fond(1)
fond(3)
fond(5)
fond(2)

Inserm Transfert Initiative (ITI) is a French investment firm, based in Paris, investing in early-stage life sciences companies. We focus on companies working on breakthrough innovations with the potential to become therapeutic solutions that will benefit society

 

puce1

Key facts

puce1

Events

 
  • €40m under management
  • Focusing on French seed investment opportunities
  • Fully dedicated to healthcare including therapeutics, medical devices and diagnostics
  • Investment range: €1m - €3m
  • Team of experienced investor professionals
  • Invested in over 25 companies since 2005
  • Strong connections with French public research institutes
 16e tremplin 02

About us

Our Story

imgaboutInserm Transfert Initiative (ITI) was created under the initiative of Inserm, the French National Institute of Health and Medical Research. Inserm is a biomedical and public health research institution with nearly 15,000 researchers, engineers, technicians and post-doctoral students as well as over 300 laboratories. It is the number one academic and clinical research organisation dedicated to human health in Europe.

In 2005, Inserm give Inserm Transfert — the Inserm private subsidiary for scientific tech-transfer — responsibility to establish a new fund, ITI, with the aim of creating a complete ecosystem around academic research institutions and addressing the need to finance early-stage life sciences companies. Together with Inserm Transfert, 3 investment funds - BPI France, Sofinnova Partners and Ventech - supported ITI’s inception.

In 2011, ITI raised €35.5 million from Inserm Transfert, BPI France (through the “Fonds National d’Amorçage”) and 10 pharmaceutical companies, making it one of the largest French life sciences seed investment funds.

ITI has developed a strong ecosystem of close partners, including:

  • Academic institutions: Inserm, CNRS, Pasteur Institute and other members of Aviesan, the French National Alliance for Life Sciences and Health,
  • Pharmaceutical and biotech companies,
  • Leading venture capital firms.

These strong connections with public and private partners will facilitate finding, seeding and growing our portfolio companies.

Team

Management Team


Portfolio

Current portfolio


1

AAV-based gene therapy for genetic diseases including Friedreich’s Ataxia (cardiomyopathy)

Aelis logo on Blanc

Cannabinoid receptor antagonist therapies for central nervous system disorders

3

Robotized systems for Transcranial Magnetic Stimulation (TMS)

4

Super-resolution modules for optical microscopes

5

Modulation of DNA repair to sensitize tumors to chemo- and radio-therapy

6

Monoclonal antibody acting on co-stimulation of T cells for autoimmunity and transplantation

7

Treatments targeting intracellular targets to control viral replication

8

Non-viral gene therapy for ocular diseases

9

Genomic services

10

Development of oxygen-carriers from a marine organism

11

New drug targets for the treatment of Inflammatory Bowel Disease

12

Therapies for acute inflammatory processes in critical care setting

13

Monoclonal antibodies for cancer

14

Small molecule for inner ear disorders (vestibular and/or cochlear disorders)

15

Detection and analysis of circulating tumor cells

shxvaccines

Second generation vaccines to prevent meningitis

16

New class of inhibitors for the treatment of autoimmune diseases

17

Treatment for rare forms of dwarfism such as achondroplasia

 18

Vaccines based on an improved peptide technology focusing on cancer indications

 

Shareholders

Inserm Transfert Initiative (ITI) raised €35,5 million in 2011 and was supported by public and private organizations as well as pharmaceutical companies. In 2005, investment funds also participated in ITI’s inception alongside Inserm Transfert.

 

NEWS

  • order

    Increase

    Decrease

Search results

2016

30/06/2016

France Biotech Unveils its New Board

11/05/2016

Effimune and OSE Pharma announce the online publication of Preclinical efficacy data with FR104 in a renal allograft model in the « Journal of the American Society of Nephrology »

15/03/2016

BioAxial announces the appointment of Georges Tabary as its president and chief executive officer

04/03/2016

Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting

24/02/2016

OSE PHARMA et EFFIMUNE proposed merger to create significant immunotherapy player

11/02/2016

Effimune and In Cell Art collaborate to develop a novel therapeutic approach in immunology

11/02/2016

Sensorion Receives French Tech Pass Certification

10/01/2016

INNATE PHARMA IN-LICENSES OREGA BIOTECH'S FIRST-IN-CLASS ANTI-CD39 CHECKPOINT INHIBITOR PROGRAM

05/01/2016

Annapurna Therapeutics to Collaborate with Weill Cornell Medicine on Gene Therapy Portfolio

06/01/2016

Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218

Contact

INSERM TRANSFERT INITIATIVE

5/7 rue Watt
75013 PARIS
France

Tel : +33 1 55 03 01 00

 Feel free to email us details of your project!

This email address is being protected from spambots. You need JavaScript enabled to view it.

Direction:

  • By metro, Line 14 - Station Bibliothèque François Mitterand
  • By RER, RER C - Station Bibliothèque François Mitterand
  • By bus, n° 62 - 89 - Station Porte de France and n° 325 - station Watt
  • By tram, n°3a - Station Porte de France